<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5804-23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FOSAMAX ONCE WEEKLY 70MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALENDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AESICA PHARMACEUTICALS GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AESICA PHARMACEUTICALS GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Organon Pharma UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->What is FOSAMAX?</p><p>FOSAMAX is a tablet containing the active substance alendronic acid (commonly called alendronate) and belongs to a group of non-hormonal medicines called bisphosphonates. FOSAMAX prevents the loss of bone that occurs in women after they have been through the menopause, and helps to rebuild bone. It reduces the risk of spine and hip fractures.</p><p>&nbsp;</p><p>What is FOSAMAX used for?</p><p>Your doctor has prescribed FOSAMAX to treat your osteoporosis. FOSAMAX reduces the risk of spine and hip fractures.</p><p>FOSAMAX is a once weekly treatment. What is osteoporosis?</p><p>Osteoporosis is a thinning and weakening of the bones. It is common in women after the menopause.</p><p>At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps to keep a woman&rsquo;s skeleton healthy. As a result, bone loss occurs and bones become weaker. The earlier a woman reaches the menopause, the greater the risk of osteoporosis.</p><p>&nbsp;</p><p>Early on, osteoporosis usually has no symptoms. If left untreated, however, it can result in broken bones. Although these usually hurt, breaks in the bones of the spine may go unnoticed until they cause height loss. Broken bones can happen during normal, everyday activity, such as lifting, or from minor injury that would not generally break normal bone. Broken bones usually occur at the hip, spine, or wrist and can lead not only to pain but also to considerable problems like stooped posture (&lsquo;dowager&rsquo;s hump&rsquo;) and loss of mobility.</p><p>&nbsp;</p><p>How can osteoporosis be treated?</p><p>As well as your treatment with FOSAMAX, your doctor may suggest you make changes to your lifestyle to help your condition, such as:</p><p>&nbsp;</p><p><em>Stopping smoking&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Smoking appears to increase the rate at which you lose bone and, therefore, may increase your risk of broken bones.</p><p>&nbsp;</p><p><em>Exercise&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Like muscles, bones need exercise to stay strong and healthy. Consult your doctor before you begin any exercise programme.</p><p>&nbsp;</p><p><em>Eating a balanced diet &nbsp;</em>Your doctor can advise you about your diet or whether you should take any dietary supplements (especially calcium and Vitamin D).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take FOSAMAX</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to alendronic acid or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have certain problems with your gullet (oesophagus - the tube that connects your mouth with your stomach) such as narrowing or difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you cannot stand or sit upright for at least 30 minutes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor has told you that you have low blood calcium</p><p>&nbsp;</p><p>If you think any of these apply to you, do not take the tablets. Talk to your doctor first and follow the advice given.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking FOSAMAX if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suffer from kidney problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have, or have recently had, any swallowing or digestive problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor has told you that you have Barrett&#39;s oesophagus (a condition associated with changes in the cells that line the lower oesophagus),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have been told you have trouble absorbing minerals in your stomach or intestines (malabsorption syndrome),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have been told you have low blood calcium,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have poor dental health, gum disease, a planned dental extraction or you don&rsquo;t receive routine dental care,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have cancer,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are undergoing chemotherapy or radiotherapy,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking angiogenesis inhibitors (such as bevacizumab, or thalidomide) which are used in the treatment of cancer,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking corticosteroids (such as prednisone or dexamethasone) which are used in the treatment of such conditions as asthma, rheumatoid arthritis, and severe allergies,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are or have been a smoker (as this may increase the risk of dental problems). You may be advised to have a dental check-up before starting treatment with FOSAMAX.</p><p>It is important to maintain good oral hygiene when being treated with FOSAMAX. You should have routine dental check-ups throughout your treatment and you should contact your doctor or dentist if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling.</p><p>&nbsp;</p><p>Irritation, inflammation or ulceration of the gullet (oesophagus &ndash; the tube that connects your mouth with your stomach) often with symptoms of chest pain, heartburn, or difficulty or pain upon swallowing may occur, especially if patients do not drink a full glass of water and/or if they lie down less than 30 minutes after taking FOSAMAX. These side effects may worsen if patients continue to take FOSAMAX after developing these symptoms.</p><p>&nbsp;</p><p>Children and adolescents</p><p>FOSAMAX should not be given to children and adolescents less than 18 years of age.</p><p>&nbsp;</p><p>Other medicines and FOSAMAX</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>It is likely that calcium supplements, antacids, and some oral medicines will interfere with the absorption of FOSAMAX if taken at the same time. Therefore, it is important that you follow the advice given in section 3.</p><p>&nbsp;</p><p>Certain medicines for rheumatism or long-term pain called NSAIDs (e.g. acetylsalicylic acid or ibuprofen) might cause digestive problems. Therefore, caution should be used when these medicines are taken at the same time as FOSAMAX.</p><p>&nbsp;</p><p>FOSAMAX with food and drink</p><p>It is likely that food and beverages (including mineral water) will make FOSAMAX less effective if taken at the same time. Therefore, it is important that you follow the advice given in section 3.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>FOSAMAX is only intended for use in postmenopausal women. You should not take FOSAMAX if you are or think you may be pregnant, or if you are breast-feeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>There have been side effects (for example blurred vision, dizziness and severe bone, muscle or joint pain) reported with FOSAMAX that may affect your ability to drive or operate machinery (see section 4).</p><p>&nbsp;</p><p>FOSAMAX contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take FOSAMAX exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Take one FOSAMAX tablet <u>once a week</u>.</p><p><strong>&nbsp;</strong></p><p>Follow these instructions carefully to make sure you will benefit from FOSAMAX.</p><p>&nbsp;</p><p><!--[if !supportLists]-->1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Choose the day of the week that best fits your schedule. Every week, take one FOSAMAX tablet on your chosen day.</p><p>&nbsp;</p><p><em>It is very important to follow instructions 2), 3), 4) and 5) to help the FOSAMAX tablet reach your stomach quickly and help reduce the chance of irritating your gullet (oesophagus - the tube that connects your mouth with your stomach).</em></p><p>&nbsp;</p><p><!--[if !supportLists]-->2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->After getting up for the day and before taking any food, drink, or other medicine, swallow your FOSAMAX tablet whole with a full glass of water only (not mineral water) (not less than</p><p>200 ml).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not take with mineral water (still or sparkling).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not take with coffee or tea.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not take with juice or milk.</p><p>&nbsp;</p><p>Do not crush or chew the tablet or allow it to dissolve in your mouth.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not lie down &mdash; stay fully upright (sitting, standing or walking) &mdash; for at least 30 minutes after swallowing the tablet. Do not lie down until after your first food of the day.</p><p>&nbsp;</p><p><!--[if !supportLists]-->4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not take FOSAMAX at bedtime or before getting up for the day.</p><p>&nbsp;</p><p><!--[if !supportLists]-->5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you develop difficulty or pain upon swallowing, chest pain, or new or worsening heartburn, stop taking FOSAMAX and contact your doctor.</p><p>&nbsp;</p><p><!--[if !supportLists]-->6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->After swallowing your FOSAMAX tablet, wait at least 30 minutes before taking your first food, drink, or other medicine of the day, including antacids, calcium supplements and vitamins. FOSAMAX is effective only if taken when your stomach is empty.</p><p>&nbsp;</p><p>If you take more FOSAMAX than you should</p><p>If you take too many tablets by mistake, drink a full glass of milk and contact your doctor immediately. Do not make yourself vomit, and do not lie down.</p><p>&nbsp;</p><p>If you forget to take FOSAMAX</p><p>If you miss a dose, just take one tablet on the morning after you remember. <em>Do not take two tablets on the same day. </em>Return to taking one tablet once a week, as originally scheduled on your chosen day.</p><p>&nbsp;</p><p>If you stop taking FOSAMAX</p><p>It is important that you take FOSAMAX for as long as your doctor prescribes the medicine.&nbsp; Since it is not known how long you should take FOSAMAX, you should discuss the need to stay on this medicine with your doctor periodically to determine if FOSAMAX is still right for you.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>See your doctor immediately </strong>if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment:</p><p>Common (may affect up to 1 in 10 people):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->heartburn; difficulty swallowing; pain upon swallowing; ulceration of the gullet (oesophagus &ndash; the tube that connects your mouth with your stomach) which can cause chest pain, heartburn or difficulty or pain upon swallowing.</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1,000 people):</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->allergic reactions such as hives; swelling of the face, lips, tongue and/or throat, possibly causing difficulty breathing or swallowing; severe skin reactions,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain in the mouth, and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis) generally associated with delayed healing and infection, often following tooth extraction. Contact your doctor and dentist if you experience such symptoms,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bone, muscle and/or joint pain which is severe.</p><p>&nbsp;</p><p>Other side effects include</p><p>Very common (may affect more than 1 in 10 people):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bone, muscle and/or joint pain which is sometimes severe.</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->joint swelling,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->abdominal pain; uncomfortable feeling in the stomach or belching after eating; constipation; full or bloated feeling in the stomach; diarrhoea; flatulence,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->hair loss; itching,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache; dizziness,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->tiredness; swelling in the hands or legs.</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->nausea; vomiting,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->irritation or inflammation of the gullet (oesophagus &ndash; the tube that connects your mouth with your stomach) or stomach,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->black or tar-like stools,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blurred vision; pain or redness in the eye,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rash; redness of the skin,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->transient flu-like symptoms, such as aching muscles, generally feeling unwell and sometimes with fever usually at the start of treatment,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->taste disturbance.</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1000 people):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->symptoms of low blood calcium levels including muscle cramps or spasms and/or tingling sensation in the fingers or around the mouth,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stomach or peptic ulcers (sometimes severe or with bleeding),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->narrowing of the gullet (oesophagus &ndash; the tube that connects your mouth with your stomach),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rash made worse by sunlight,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->mouth ulcers when the tablets have been chewed or sucked.</p><p>&nbsp;</p><p>Very rare (may affect up to 1 in 10,000 people):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could be signs of bone damage in the ear.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA&rdquo;. By reporting side effects,&nbsp; you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg; C. Store in the original blister in order to protect from Moisture and Light.</p><p>&nbsp;</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->What FOSAMAX contains</p><p>The active substance is alendronic acid. Each tablet contains 70 mg alendronic acid (as sodium trihydrate).</p><p>&nbsp;</p><p>The other ingredients are microcrystalline cellulose, lactose anhydrous, croscarmellose sodium and magnesium stearate. (See section 2 &quot;FOSAMAX contains lactose&quot;)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FOSAMAX tablets are available as oval, white tablets marked with an outline of a bone image on one side and ‘31’ on the other.

The tablets are supplied in aluminium blisters in cartons in the following pack sizes: 2, 4, 8, 12 or 40 tablets.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Merck Sharp &amp; Dohme Ltd.</p><p>Hertford Road, Hoddesdon</p><p>Hertfordshire EN11 9BU</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>AESICA Pharmaceuticals GMBH</p><p>Galileistrasse 6, Zwickau, D-08056, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in February 2018.
Version No. (03)


HOW CAN YOU OBTAIN MORE INFORMATION ABOUT FOSAMAX?

This leaflet gives you the most important patient information about FOSAMAX. If you have any questions after you have read it, ask your doctor or pharmacist, who will give you further information.


To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA
o Fax: +966-11-205-7662
o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.
Council of Arab Health Ministers Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو </strong><strong>فوساماكس &nbsp;</strong></p><p>فوساماكس قرص يحتوي على المادة الفعّالة، حمض الأليندرونيك (يعرف بالندرونات) وينتمي إلى مجموعة أدوية غير هورمونيّة تُعرَف بالبيسفوسفونات. فهو يمنع فقدان العظام لدى المرأة بعد سن اليأس ويُساعد على إعادة تكوين العظام. كما يحدّ من خطر التعرّض لكسر في الورك وفي العامود الفقري.</p><p>&nbsp;</p><p><strong>لمَ يُستخدَم </strong><strong>فوساماكس &nbsp;</strong></p><p>وصف لك الطبيب فوساماكس &nbsp;لمعالجة ترقّق العظام. فهو يحدّ من خطر التعرّض لكسور في الورك وفي العامود الفقري.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>فوساماكس &nbsp;علاج يُعطى مرّة واحدة في الأسبوع.</strong></p><p>&nbsp;</p><p><strong>ما هو ترقّق العظام؟</strong></p><p>هو داء يُصيب العظام، يؤدّي إلى ترقّقها ووهنها. إنّه داء شائع لدى النساء بعد سن اليأس. في سن اليأس، يتوقف المبيضَان عن إنتاج الهورمون النسائي، الأستروجين، الذي يُساهم &nbsp;في الابقاء على صحّة الهيكل العظمي للمرأة. ونتيجةً لذلك، تفقد &nbsp;العظام كثافتها وتُصبح العظام أضعف. وكلّما أصيبت المرأة بسن اليأس في وقتٍ مُبكر، زاد خطر الإصابة بترقّق العظام.</p><p>وفي مرحلة مبكرة، لا يكون لداء ترقّق العظام أي عوارض عادةً. لكن، في حال عدم معالجته، يُمكن أن يُسبّب كسورًا في العظام. صحيح أنّ هذه الكسور تكون مؤلمة عادةً. لكن، قد لا تتمّ ملاحظة كسور العامود الفقري إلا عندما تُسبّب فقدانًا للطول. قد تتعرّض لكسور في العظام في الأنشطة الاعتياديّة واليوميّة، مثل حمل الأغراض، أو التعرّض لإصابة طفيفة لا تُسبّب عادةً كسرًا في العظام. تُصيب الكسور عادةً عظام الورك، أو العامود الفقري، أو المعصم، وقدلا تُسبّب الألم &nbsp;فقط ، إنّما قد تُسبّب مشاكلَ كبيرة، مثل التحدب وفقدان الحركة.</p><p>&nbsp;</p><p><strong>كيفيّة معالجة ترقّق العظام</strong></p><p>بالإضافة إلى علاجك بواسطة فوساماكس ، قد يقترح عليك الطبيب أن تُدخل تغييرات إلى أسلوب حياتك لتحسين حالتك، مثل:</p><p>-<em>التوقّف عن التدخين</em>: يبدو أن التدخين يزيد من وتيرة فقدانك لكثافة العظام وبالتالي، قد يزيد من خطر تعرّضك لكسور في العظام.</p><p>-<em> التمارين الرياضية</em>: على غرار العضلات، تحتاج العظام إلى التمارين الرياضية لتبقى قويّةً وصحيّةً. استشر الطبيب قبل أن تبدأ أي برنامج تمرين رياضي.</p><p>- <em>اعتماد نظام غذائي متوازن</em>: قد ينصحك الطبيب بشأن نظامك الغذائي أو إذا ما كان عليك تناول مكمّلات غذائيّة (بشكل خاص، الكالسيوم وفيتامين د).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول فوساماكس &nbsp;في الحالات التالية:</p><p dir="RTL">لا تتناول فوساماكس &nbsp;في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسيّة من حمض الأليندرونيك أو من أي مكونات أخرى في هذا الدواء (انظر البند رقم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك بعض المشاكل في المريء (وهي القناة التي تصل فمك بمعدتك)، مثل تضيّق المريء أو صعوبة في البلع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت عاجزًا عن الوقوف أو عن الجلوس بوضع قائم لمدّة 30 دقيقة على الأقل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قال لك الطبيب إن مستوى الكالسيوم في الدم لديك متدنٍّ.</p><p dir="RTL">في حال كنت تعتبر أن الحالات المذكورة أعلاه ذكرها عليك، لا تتناول الأقراص، بل اتّصل بالطبيب أولاً واتّبع النصائح التي يُسديها إليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المخاطر و الاحتياطات </strong></p><p dir="RTL">إتّصل بالطبيب أو بالصيدلي قبل تناول فوساماكس إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تُعاني من مشاكل في الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تُعاني او إذا تعرضت مؤخراً لمشاكل في البلع والهضم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بأنّك مُصاب بمريء بارت (وهي حالة مرتبطة بالتغيّرات في الخلايا المبطنة لأسفل المريء(.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بأنّ لديك مشكلة في امتصاص المعادن في المعدة أو الأمعاء (متلازمة سوء الامتصاص)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بأنّ مستوى الكالسيوم في الدم لديك منخفض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ضعف صحة أسنانك، مصاباً بأمراض اللثة، لديك موعد مسبق لخلع الاسنان، أو لا تولي عناية روتينية لأسنانك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُصاب بالسرطان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخضع لعلاج كيمائي أو إشعاعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول مثبطات تكوين الأوعية الدموية المتجددة ( مثل بيفاسيزوماب أو ثاليدوميد)، التي تستخدم لعلاج السرطان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول الكورتيكوستيرويدات (مثل البردنيزون أو الديكساميتازون)، التي تستخدم لعلاج بعص الأمراض مثل الربو، التهاب المفاصل&quot;الروماتيزم ، و تفعلات الحساسية الشديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدخن أو كنت مدخنا (بما أن ذلك قد يزيد من خطر تعرّضك لمشاكل الأسنان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُطلب منك زيارة طبيب الأسنان للمراجعة قبل مباشرة العلاج بواسطة فوساماكس .</p><p dir="RTL">من المهمّ أن تُحافظ على صحة فمك عند خضوعك لعلاج بواسطة فوساماكس . عليّك الخضوع لمراجعة روتينيّة لدى طبيب الأسنان خلال علاجك وعليك الاتصال بالطبيب أو بطبيب الأسنان في حال تعرّضت لأي مشكلة في فمك أو في أسنانك، مثل أسنان رخوة، أو ألم، أو تورّم.</p><p dir="RTL">غالبًا ما يترافق تهيّج المريء (القناة التي تصل فمك بمعدتك) أو التهابه أو تقرّحه مع أعراض ألم في الصدر، أو حرقة في المعدة، أو صعوبة أو ألم عند البلع، لا سيّما إذا كان المرضى لا يشربون كوبًا كاملاً من الماء و/أو إذا كانوا يستلقون قبل مرور 30 دقيقة بعد تناول فوساماكس . قد تزداد هذه الآثار الجانبيّة سوءًا في حال واصل المرضى تناول فوساماكس &nbsp;بعد تعرّضهم لهذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُعطى فوساماكس &nbsp;للأطفال والمراهقين دون 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع فوساماكس </strong></p><p dir="RTL">أطلع الطبيب أو الصيدلي إذا كنت تتناول في الوقت الحالي أو تناولت مؤخّرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">من المحتمل أن تؤثّر مكمّلات الكلسيوم، ومُضادات الحموضة، وبعض الأدوية الأخرى التي تُعطى عبر الفم على امتصاص الجسم لفوساماكس &nbsp;في حال تناولها في الوقت نفسه. وبالتالي، من المهمّ اتّباع النصائح المُعطاة في البند 3.</p><p dir="RTL">كما قد تُسبب بعض الأدوية لمعالجة داء التهاب المفاصل أو لمعالجة ألم طويل الأمد، التي تُعرَف بمضادات الالتهاب اللاستيرويديّة (مثل حمض الأسيتيل ساليسيليك والايبوبروفين) مشاكل في الهضم. وبالتالي، يجب توخّي الحذر عند تناول الأدوية في الوقت نفسه مع فوساماكس .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول فوساماكس &nbsp;مع الطعام والمشروبات</strong></p><p dir="RTL">من المحتمل أن الطعام والمشروبات (بما في ذلك المياه المعدنيّة) ستحدّ من فاعليّة فوساماكس &nbsp;في حال تناولها في الوقت نفسه. وبالتالي، من المهمّ اتّباع النصائح في البند 3.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يُستخدَم فوساماكس &nbsp;فقط من قبل المرأة في سن اليأس. يجب عدم تناول فوساماكس إذا كنتِ حاملًا أو تظنّين أنّك قد تكونين حاملًا أو مُرضعًا .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><strong> </strong></p><p dir="RTL">لفوساماكس &nbsp;أعراض جانبيّة (بما في ذلك عدم وضوح الرؤية، والدوخة، والألم الحاد في العظام، أو العضل، أو المفاصل) و التي قد تؤثّر على القدرة على قيادة الآلات وتشغيلها (اقرأ البند 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فوساماكس &nbsp;على اللاكتوز </strong></p><p dir="RTL">إذا قال لك الطبيب إنّك لا تتقبَّل بعض السكريّات، إتّصل بالطبيب قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp; تناول فوساماكس&nbsp; تمامًا حسب ارشادات طبيبك. تحقق من طبيبك أو الصيدلاني إذا لم تكن متاكدًا.</p><p>&nbsp;</p><p><strong><u>تناول قرص فوساماكس &nbsp;</u></strong><strong><u>مرة واحدة اسبوعياً</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>اتّبع هذه التعليمات بتأنٍّ للحرص على الاستفادة من فوساماكس .</p><p><!--[if !supportLists]-->1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إختر يومًا في الأسبوع يُناسب جدولك الزمني. في كل أسبوع، تناول قرص فوساماكس &nbsp;في اليوم الذي اخترته.</p><p><em>من المهمّ جدًّا اتّباع التعليمات 2) و3) و4) و5) لمساعدة قرص فوساماكس &nbsp;للوصول إلى المعدة بشكل سريع والمساعدة على تقليص تهيّج المريء (القناة التي تصل الفم بالمعدة).</em></p><p><!--[if !supportLists]-->2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بعد الاستيقاظ لمباشرة حياتك اليوميّة وقبل تناول أي طعام أو مشروب أو أدوية أخرى، ابتلع قرص فوساماكس &nbsp;بالكامل مع كوب كامل من الماء فقط (لا مياه معدنيّة) (ليس أقل من 200 مل):</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تتناوله مع مياه معدنيّة (عاديّة أو فوّارة)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تتناوله مع القهوة أو الشاي</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تتناوله مع العصير أو الحليب</p><p>لا تطحن القرص أو تمضغه أو تسمح بانحلاله في الفم.</p><p><!--[if !supportLists]-->3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تستلقِ &ndash; إبقَ بوضع قائم (الجلوس، أو الوقوف، أو المشي) &ndash; لمدّة 30 دقيقة على الأقل بعد ابتلاع القرص. لا تستلقِ حتى تناول وجبة اليوم الأولى.</p><p><!--[if !supportLists]-->4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تتناول فوساماكس &nbsp;قبل النوم وقبل الاستيقاظ لمباشرة حياتك اليوميّة.</p><p><!--[if !supportLists]-->5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حال التعرّض لصعوبة أو ألم عند البلع، أو ألم في الصدر، أو التعرّض &nbsp;لحرقة حموضة جديدة أو ازديادها، توقّف عن تناول فوساماكس &nbsp;واتّصل بالطبيب.</p><p><!--[if !supportLists]-->6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بعد ابتلاع قرص فوساماكس ، انتظر 30 دقيقة على الأقل قبل تناول وجبة الطعام الأولى، أو المشروب، أو أي دواء آخر خلال اليوم، بما في ذلك مضادات الحموضة، ومكمّلات &nbsp;الكالسيوم ، والفيتامينات. لا يُعتبَر فوساماكس &nbsp;فاعلاً إلا في حال تناول الدواء والمعدة فارغة.</p><p><strong>في حال تناولت جرعة زائدة من فوساماكس</strong></p><p>في حال تناول جرعة مفرطة بطريق الخطأ ، تناول كوب حليب كاملاً واتّصل بالطبيب فورًا. لا تجعل نفسك تتقيّأ ولا تستلقي.</p><p><strong>&nbsp;</strong></p><p><strong>في حال نسيت تناول جرعة فوساماكس </strong></p><p>في حال فوّت جرعةً، تناول قرصًا في الصباح ما أن تتذكّر. <em>لا تتناول قرصَيْن في اليوم نفسه</em>. تناول مجدّدًا قرصًا واحدًا مرةً في الأسبوع، كما هو مُخطَّط له في اليوم المُحدَّد.</p><p>&nbsp;</p><p><strong>في حال توقّفت عن تناول فوساماكس &nbsp;</strong></p><p>من المهمّ أن تستمر بتناول فوساماكس &nbsp;طوال المدة التي وصفها لك الطبيب&nbsp; . بما أنّه من غير المعروف الفترة الزمنيّة التي عليك تناول فوساماكس &nbsp;فيها، عليك مناقشة الحاجة إلى البقاء على هذا الدواء &nbsp;عند مراجعة الطبيب بشكل دوري&nbsp; للتأكد إذا ما كان فوساماكس &nbsp;لا يزال ملائمًا لك.</p><p>في حال كان لديك أسئلة إضافيّة حول استخدام هذا الدواء، اتّصل بالطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>على غرار جميع الأدوية، قد يسبب تناول هذا الدواء أعراضًا جانبية محتملة على الرغم من أنها قد لا تحدث لجميع الأشخاص.</p><p>راجع الطبيب فورًا في حال لاحظت أي أعراض جانبية، قد تكون خطرة و قد تحتاج إلى علاج طبي طارئ:</p><p><u>الأعراض الشائعة (قد تؤثّر على شخص واحد من أصل 10):</u></p><ul><li>حرقة في المعدة؛ صعوبة في البلع؛ ألم عند البلع؛ تقرّح المريء (المريء &ndash; القناة التي تصل الفم بالمعدة) الذي قد يُسبّب ألمًا في الصدر، أو &nbsp;حرقة في المعدة، أو صعوبة أو ألمًا عند البلع.</li></ul><p>&nbsp;</p><p><u>الأعراض النادرة (قد تؤثّر على شخص واحد من أصل 1000):</u></p><ul><li>ردود الفعل الحساسيّة، مثل الشرى؛ انتفاخ الوجه، أو الشفتَيْن، أو اللسان، و/أو الحنجرة، ممّا قد يُسبّب صعوبة في التنفّس أو البلع؛ ردود فعل جلديّة حادة</li><li>ألم في الفم و/أو الفك، أو تورّم، أو تقرّحات داخل الفم، التنميل أو الشعور بثقل في الفك أو وجود سن رخو. قد يُشير ذلك إلى تعرّض العظام في الفك للضرر (نَخَرٌ عَظْمِيّ)، يرتبط عادةً بالتهاب أو شفاء متأخّر، غالبًا ما يليه استئصال السن. إتّصل بالطبيب وبطبيب الأسنان في حال التعرّض لمثل هذه الأعراض.</li><li>التعرّض لكسر غير اعتيادي في عظم الفخذ، لا سيّما لدى المرضى الخاضعين لعلاج طويل الأمد لمعالجة ترقّق العظام في حالات نادرة. اتّصل بالطبيب في حال اختبرت ألمًا أو وهنًا أو انزعاجًا في فخذك، أو وركك، أو أربيّتك بما أنّه قد يُعطي مؤشّرًا مبكرًا لكسر مُحتمَل في عظم الفخذ.</li><li>ألم حاد في العظام و/أو العضلات و/أو المفاصل.</li></ul><p>&nbsp;</p><p><strong>تشمل الأعراض الجانبيّة الأخرى ما يلي:</strong></p><p><u>الأعراض الشائعة جدًّا (التي قد تؤثّر على أكثر من شخص من أصل 10):</u></p><ul><li>ألم في العظام، و/أو العضلات، و/أو المفاصل، يكون حادًا أحيانًا</li></ul><p><u>الأعراض الشائعة (التي قد تؤثّر على شخص من أصل 10):</u></p><ul><li>&nbsp;ورم&nbsp; المفاصل</li><li>ألم في البطن؛ شعور بالانزعاج في المعدة أو التجشّؤ بعد الأكل؛ الامساك؛ الشعور بالامتلاء أو بالانتفاخ في المعدة؛ الاسهال؛ الغازات،</li><li>فقدان الشعر، الحكاك،</li><li>الصداع؛ الدوخة،</li><li>الوهن؛ انتفاخ اليدَيْن أو الساقَيْن.</li></ul><p><u>الأعراض غير الشائعة (التي قد تؤثّر على شخص من أصل 100):</u></p><ul><li>الغثيان؛ التقيّؤ</li><li>التهيّج أو الالتهاب في المريء (القناة التي تصل الفم بالمعدة) أو في المعدة</li><li>براز أسود أو قطراني</li><li>تغيّم الرؤية؛ ألم أو إحمرار في العين</li><li>طفح جلدي؛ إحمرار الجلد</li><li>أعراض مؤقّتة شبيهة بأعراض الرشح، مثل الألم في العضلات، والشعور العام بالانزعاج، يترافق أحيانًا مع بداية العلاج عادةً</li><li>اضطراب حاسة الذوق</li></ul><p><u>الأعراض النادرة (التي قد تؤثّر على شخص من أصل 1000):</u></p><ul><li>أعراض مستوى &nbsp;كالسيوم منخفض في الدم، بما في ذلك التشنّجات أو الانقباضات العضليّة و/أو الشعور بالوخز في الأصابع أو في مُحيط الفم</li><li>تقرّحات في المعدة أو &nbsp;&nbsp;&nbsp;&nbsp;الأثني عشر(تكون حادةً أحيانًا أو يُرافقها نزيف)</li><li>تضيّق المريء (القناة التي تصل الفم بالمعدة)</li><li>طفح جلدي يزداد سوءًا مع التعرّض لأشعّة الشمس</li><li>تقرّحات الفم عند مضغ الأقراص أو مصّها.</li></ul><p><u>&nbsp;</u></p><p><u>الأعراض النادرة جداً (التي قد تؤثّر على شخص من أصل 10000):</u></p><ul><li>أخبر الطبيب إذا كان لديك ألم في الأذن، إفرازات من الأذن، و / أو التهاب في الأذن. من الممكن أن تكون هذه أعراض تلف العظام في الأذن.</li></ul><p>&nbsp;</p><p><strong>الابلاغ عن الأعراض الجانبيّة المحتملة:</strong></p><p>اتّصل بالطبيب أو الصيدلي أو الممرض في حال تعرّضك لأي أعراض جانبيّة محتملة بالإضافة إلى تلك غير المذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبيّة مباشرة من خلال &quot; المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot;</p><p>&nbsp;يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء من خلال الابلاغ عن الأعراض الجانبيّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p>يحفظ في درجة حرارة أقل ٣۰ درجة مئوية .</p><p>يحفظ في العبوة الأصلية لحمايته من الضوء والرطوبة.</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية و الشريط بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير لحماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعّالة هي حمض ألندرونيك. يحتوي كل قرص على 70 ملغم من حمض ألندرونيك (على شكل ألندرونات صوديوم تراي هايدريت).</p><p>المكوّنات الأخرى هي:</p><p>ميكروكريستالين سيليلوز ، لاكتوز لا مائي، صوديوم كروسكارميلوز، وستيرات المغنيسيوم. (راجع البند 2 &quot;يحتوي فوساماكس &nbsp;على اللاكتوز).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو المظهر الخارجي لأقراص دواء فوساماكس و ما هي محتويات العبوة أقراص فوساماكس بيضوية الشكل وبيضاء اللون، مطبوع على جهة منها صورة عظمة، و&quot;31&quot; على الجهة الأخرى. الأقراص متوفّرة في شرائط من الألمينيوم في علب من كرتون من الأحجام التالية: 2، أو 4، أو 8، أو 12، أو 40 قرصًا. قد لا يتمّ تسويق الأحجام كلّها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة</strong><strong> </strong><strong>المالكة</strong><strong> </strong><strong>لحقوق</strong><strong> </strong><strong>التسويق</strong><strong>:</strong></p><p>ميرك شارب ودوم المحدودة،</p><p>طريق هيرتفورد، هوديسدون، هيرتفوردشاير</p><p>إي إن 11 9 بي يو، المملكة المتحدة</p><p><strong>&nbsp;</strong></p><p><strong>الشركة الصانعة:</strong></p><p>أسيكا للصناعات الدوائية جي أم بي إتش<br />جاليليستراسي 6، تسفيكاو، دي-08056، ألمانيا</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            لقد تمت مراجعة هذه النشرة بتاريخ فبراير 2018
الإصدار رقم (3)

كيف يمكن الحصول على مزيد من المعلومات حول فوساماكس؟ 
 تمنحك هذه النشرة أهم معلومات المريض حول فوساماكس. إذا كان لديك أي أسئلة بعد القراءة، اسأل طبيبك أو الصيدلي، الذي سيقدم لك المزيد من المعلومات.

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية، الهيئة العامة للغذاء والدواء 
فاكس: +966-11-205-7662
للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات . هاتف: +966-11-20382222	
تحويلة: 2317-2356-2353-2354-2334-2340
الهاتف المجاني: 8002490000  
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: www.sfda.gov.sa/npc
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.
(إن هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خِلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FOSAMAX® Once Weekly 70 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 70 mg alendronic acid (as sodium trihydrate).
Excipients with known effect:
Each tablet contains 113.4 mg lactose (as lactose anhydrous).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

Oval white tablets, marked with an outline of a bone image on one side, and ‘31’ on the other.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FOSAMAX is indicated in adults for the treatment of postmenopausal osteoporosis. FOSAMAX reduces the risk of vertebral and hip fractures.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The recommended dosage is one 70 mg tablet once weekly.</p><p>Patients should be instructed that if they miss a dose of FOSAMAX Once Weekly, they should take one tablet on the morning after they remember. They should not take two tablets on the same day but should return to taking one tablet once a week, as originally scheduled on their chosen day.</p><p>The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of &lsquo;Fosamax&rsquo; on an individual patient basis, particularly after 5 or more years of use.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate. Therefore no dosage adjustment is necessary for the elderly.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dosage adjustment is necessary for patients with creatinine clearance greater than 35 ml/min. Alendronate is not recommended for patients with renal impairment where creatinine clearance is less than 35 ml/min, due to lack of experience.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of FOSAMAX in children less than 18 years of age has not been established. This medicinal product should not be used in children less than 18 years of age. Currently, available data for alendronic acid in the paediatric population is described in section 5.1.</p><p>Paediatric population:</p><p>The safety and efficacy of FOSAMAX</p><p>in children less than 18 years of age has not been established. This medicinal product should not be used in children less than 18 years of age. Currently available data for alendronic acid in the paediatric population is described in section 5.1).</p><p>&nbsp;</p><p><u>Method of administration</u> Oral use.</p><p><em>To permit adequate absorption of alendronate:</em></p><p><em>&nbsp;</em></p><p>FOSAMAX must be taken at least 30 minutes before the first food, beverage, or medicinal product of the day with plain water only. Other beverages (including mineral water), food and some medicinal products are likely to reduce the absorption of alendronate (see section 4.5).</p><p>&nbsp;</p><p><em>To facilitate delivery to the stomach and thus reduce the potential for local and oesophageal irritation/adverse experiences (see section 4.4):</em></p><p><em>&nbsp;</em></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->FOSAMAX should only be swallowed upon arising for the day with a full glass of water (not less than 200 ml).</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Patients should only swallow FOSAMAX whole. Patients should not crush or chew the tablet or allow the tablet to dissolve in their mouths because of a potential for oropharyngeal ulceration.</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Patients should not lie down until after their first food of the day which should be at least 30 minutes after taking the tablet.</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Patients should not lie down for at least 30 minutes after taking FOSAMAX.</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->FOSAMAX should not be taken at bedtime or before arising for the day.</p><p>&nbsp;</p><p>Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>FOSAMAX Once Weekly 70 mg has not been investigated in the treatment of glucocorticoid- induced osteoporosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

-	Abnormalities of the oesophagus and other factors which delay oesophageal emptying such as stricture or achalasia.

-	Inability to stand or sit upright for at least 30 minutes.

-	Hypocalcaemia.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Upper gastrointestinal adverse reactions</u></p><p>&nbsp;</p><p>Alendronate can cause local irritation of the upper gastro-intestinal mucosa. Because there is a potential for worsening of the underlying disease, caution should be used when alendronate is given to patients with active upper gastro-intestinal problems, such as dysphagia, oesophageal disease, gastritis, duodenitis, ulcers, or with a recent history (within the previous year) of major gastro-intestinal disease such as peptic ulcer, or active gastro-intestinal bleeding, or surgery of the upper gastro-intestinal tract other than pyloroplasty (see section 4.3). In patients with known Barrett&#39;s oesophagus, prescribers should consider the benefits and potential risks of alendronate on an individual patient basis.</p><p>&nbsp;</p><p>Oesophageal reactions (sometimes severe and requiring hospitalisation), such as oesophagitis, oesophageal ulcers and oesophageal erosions, rarely followed by oesophageal stricture, have been reported in patients receiving alendronate. Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing or retrosternal pain, new or worsening heartburn.</p><p>&nbsp;</p><p>The risk of severe oesophageal adverse experiences appears to be greater in patients who fail to take alendronate properly and/or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation. It is very important that the full dosing instructions are provided to, and understood by the patient (see section 4.2). Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems.</p><p>&nbsp;</p><p>While no increased risk was observed in extensive clinical trials, there have been rare (post- marketing) reports of gastric and duodenal ulcers, some severe and with complications.</p><p>&nbsp;</p><p><u>Osteonecrosis of the jaw</u></p><p>Osteonecrosis of the jaw, generally associated with tooth extraction <u>and</u>/or local infection (including osteomyelitis), has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphosphonates. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates.</p><p>&nbsp;</p><p>The following risk factors should be considered when evaluating an individual&#39;s risk of developing osteonecrosis of the jaw:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->potency of the bisphosphonate (highest for zoledronic acid), route of administration (see above) and cumulative dose</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and poorly fitting dentures.</p><p>&nbsp;</p><p>A dental examination with appropriate preventive dentistry should be considered prior to treatment with oral bisphosphonates in patients with poor dental status.</p><p>&nbsp;</p><p>While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no</p><p>data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk</p><p>&nbsp;</p><p>of osteonecrosis of the jaw. Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.</p><p>&nbsp;</p><p>During bisphosphonate treatment, all patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling.</p><p>&nbsp;</p><p><u>Osteonecrosis of the external auditory canal</u></p><p>Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly</p><p>in association with long-term therapy. Possible risk factors for osteonecrosis of the external</p><p>auditory canal include steroid use and chemotherapy and/or local risk factors such as infection</p><p>or trauma. The possibility of osteonecrosis of the external auditory canal should be considered</p><p>in patients receiving bisphosphonates who present with ear symptoms such as pain or</p><p>discharge, or chronic ear infections.</p><p>&nbsp;</p><p><u>Musculoskeletal pain</u></p><p>Bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates. In post- marketing experience, these symptoms have rarely been severe and/or incapacitating (see section 4.8). The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.</p><p>&nbsp;</p><p><u>Atypical fractures of the femur</u></p><p>Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique, fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture.</p><p>Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.</p><p>&nbsp;</p><p>During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Alendronate is not recommended for patients with renal impairment where creatinine clearance is less than 35 ml/min, (see section 4.2).</p><p>&nbsp;</p><p><u>Bone and mineral metabolism</u></p><p>Causes of osteoporosis other than oestrogen deficiency and ageing should be considered.</p><p>&nbsp;</p><p>Hypocalcaemia must be corrected before initiating therapy with alendronate (see section 4.3). Other disorders affecting mineral metabolism (such as vitamin D deficiency and</p><p>&nbsp;</p><p>hypoparathyroidism) should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcaemia should be monitored during therapy with FOSAMAX.</p><p>&nbsp;</p><p>Due to the positive effects of alendronate in increasing bone mineral, decreases in serum calcium and phosphate may occur especially in patients taking glucocorticoids in whom calcium absorption may be decreased. These are usually small and asymptomatic. However, there have been rare reports of symptomatic hypocalcaemia, which have occasionally been severe and often occurred in patients with predisposing conditions (e.g. hypoparathyroidism, vitamin D deficiency and calcium malabsorption).</p><p>&nbsp;</p><p>Ensuring adequate calcium and vitamin D intake is particularly important in patients receiving glucocorticoids.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>No other interactions with medicinal products of clinical significance are anticipated. A number of patients in the clinical trials received oestrogen (intravaginal, transdermal, or oral) while taking alendronate. No adverse experiences attributable to their concomitant use were identified.</p><p>&nbsp;</p><p>Since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.</p><p>&nbsp;</p><p>Although specific interaction studies were not performed, in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of clinical adverse interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of alendronate in pregnant women. Studies in animals have shown reproductive toxicity. Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia (see section 5.3).</p><p>FOSAMAX should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether alendronate/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Alendronate should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone, and hence, the amount available for release back into the systemic circulation, is directly related to the dose and duration of bisphosphonate use (see section 5.2). There are no data on foetal risk in humans. However, there is a theoretical risk of foetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FOSAMAX has no or negligible direct influence on the ability to drive and use machines. Patients may experience certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or joint pain (see section 4.8)) that may influence the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In a one-year study in post-menopausal women with osteoporosis the overall safety profiles of FOSAMAX Once Weekly 70 mg (n=519) and alendronate 10 mg/day (n=370) were similar.</p><p>&nbsp;</p><p>In two three-year studies of virtually identical design, in post-menopausal women (alendronate 10 mg: n=196, placebo: n=397) the overall safety profiles of alendronate 10 mg/day and placebo were similar.</p><p>&nbsp;</p><p>Adverse experiences reported by the investigators as possibly, probably or definitely drug- related are presented below if they occurred in &sup3;1% in either treatment group in the one-year study, or in &sup3;1% of patients treated with alendronate 10 mg/day and at a greater incidence than in patients given placebo in the three-year studies:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:69.7pt; vertical-align:top; width:139.1pt"><p>&nbsp;</p></td><td style="height:69.7pt; vertical-align:top; width:77.25pt"><p>One year study FOSAMAX Once Weekly 70 mg (n=519)</p><p>%</p></td><td style="height:69.7pt; vertical-align:top; width:100px"><p>One year study alendronate 10 mg/day (n=370)</p><p>%</p></td><td style="height:69.7pt; vertical-align:top; width:102px"><p>Three years&nbsp; study alendronate 10 mg/day (n=196)</p><p>%</p></td><td style="height:69.7pt; vertical-align:top; width:83.6pt"><p>Three years&nbsp; study&nbsp;</p><p>Placebo (n=397)</p><p>%</p></td></tr><tr><td style="height:27.8pt; vertical-align:top; width:139.1pt"><p>&nbsp;</p><p><em>Gastro-intestinal</em></p></td><td style="height:27.8pt; vertical-align:top; width:77.25pt"><p>&nbsp;</p></td><td style="height:27.8pt; vertical-align:top; width:100px"><p>&nbsp;</p></td><td style="height:27.8pt; vertical-align:top; width:102px"><p>&nbsp;</p></td><td style="height:27.8pt; vertical-align:top; width:83.6pt"><p>&nbsp;</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>abdominal pain</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>3.7</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>3.0</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>6.6</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>4.8</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>Dyspepsia</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>2.7</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>2.2</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>3.6</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>3.5</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>acid regurgitation</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>1.9</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>2.4</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>2.0</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>4.3</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>Nausea</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>1.9</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>2.4</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>3.6</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>4.0</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>abdominal distention</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>1.0</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>1.4</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>1.0</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>0.8</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>Constipation</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>0.8</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>1.6</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>3.1</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>1.8</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>Diarrhoea</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>0.6</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>0.5</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>3.1</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>1.8</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:139.1pt"><p>Dysphagia</p></td><td style="height:13.8pt; vertical-align:top; width:77.25pt"><p>0.4</p></td><td style="height:13.8pt; vertical-align:top; width:100px"><p>0.5</p></td><td style="height:13.8pt; vertical-align:top; width:102px"><p>1.0</p></td><td style="height:13.8pt; vertical-align:top; width:83.6pt"><p>0.0</p></td></tr><tr><td style="height:13.55pt; vertical-align:top; width:139.1pt"><p>Flatulence</p></td><td style="height:13.55pt; vertical-align:top; width:77.25pt"><p>0.4</p></td><td style="height:13.55pt; vertical-align:top; width:100px"><p>1.6</p></td><td style="height:13.55pt; vertical-align:top; width:102px"><p>2.6</p></td><td style="height:13.55pt; vertical-align:top; width:83.6pt"><p>0.5</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:14.05pt; vertical-align:top; width:112.3pt"><p>Gastritis</p></td><td style="height:14.05pt; vertical-align:top; width:69.9pt"><p>0.2</p></td><td style="height:14.05pt; vertical-align:top; width:104.1pt"><p>1.1</p></td><td style="height:14.05pt; vertical-align:top; width:51.85pt"><p>0.5</p></td><td style="height:14.05pt; vertical-align:top; width:49.15pt"><p>1.3</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:112.3pt"><p>gastric ulcer</p></td><td style="height:13.8pt; vertical-align:top; width:69.9pt"><p>0.0</p></td><td style="height:13.8pt; vertical-align:top; width:104.1pt"><p>1.1</p></td><td style="height:13.8pt; vertical-align:top; width:51.85pt"><p>0.0</p></td><td style="height:13.8pt; vertical-align:top; width:49.15pt"><p>0.0</p></td></tr><tr><td style="height:17.9pt; vertical-align:top; width:112.3pt"><p>oesophageal ulcer</p></td><td style="height:17.9pt; vertical-align:top; width:69.9pt"><p>0.0</p></td><td style="height:17.9pt; vertical-align:top; width:104.1pt"><p>0.0</p></td><td style="height:17.9pt; vertical-align:top; width:51.85pt"><p>1.5</p></td><td style="height:17.9pt; vertical-align:top; width:49.15pt"><p>0.0</p></td></tr></tbody></table><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1032"
 style='position:absolute;left:0;text-align:left;margin-left:362.1pt;
 margin-top:-51.75pt;width:2.3pt;height:152.6pt;z-index:-251657216;
 mso-position-horizontal-relative:page' coordorigin="7242,-1035" coordsize="46,3052"
 o:allowincell="f">
 <v:shape id="_x0000_s1033" style='position:absolute;left:7279;top:-1026;
  width:20;height:3035;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="20,3035" o:allowincell="f"
  path="m,hhl,3035e" filled="f" strokeweight=".82pt">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1034" style='position:absolute;left:7250;top:-1026;
  width:20;height:3035;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="20,3035" o:allowincell="f"
  path="m,hhl,3035e" filled="f" strokeweight=".82pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="4" height="205" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[endif]--><em>Musculoskeletal</em></p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:12.7pt; vertical-align:top; width:124.5pt"><p>musculoskeletal (bone,</p></td><td style="height:12.7pt; vertical-align:top; width:57.7pt"><p>2.9</p></td><td style="height:12.7pt; vertical-align:top; width:78.0pt"><p>3.2</p></td><td style="height:12.7pt; vertical-align:top; width:77.95pt"><p>4.1</p></td><td style="height:12.7pt; vertical-align:top; width:49.15pt"><p>2.5</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:124.5pt"><p>muscle or joint) pain</p></td><td style="height:13.8pt; vertical-align:top; width:57.7pt"><p>&nbsp;</p></td><td style="height:13.8pt; vertical-align:top; width:78.0pt"><p>&nbsp;</p></td><td style="height:13.8pt; vertical-align:top; width:77.95pt"><p>&nbsp;</p></td><td style="height:13.8pt; vertical-align:top; width:49.15pt"><p>&nbsp;</p></td></tr><tr><td style="height:17.9pt; vertical-align:top; width:124.5pt"><p>muscle cramp</p></td><td style="height:17.9pt; vertical-align:top; width:57.7pt"><p>0.2</p></td><td style="height:17.9pt; vertical-align:top; width:78.0pt"><p>1.1</p></td><td style="height:17.9pt; vertical-align:top; width:77.95pt"><p>0.0</p></td><td style="height:17.9pt; vertical-align:top; width:49.15pt"><p>1.0</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Neurological</em></p><p>Headache&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.5</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse experiences have also been reported during clinical studies and/or post-marketing use:</p><p>&nbsp;</p><p>Frequencies are defined as: Very common (&ge;1/10), Common (&ge;1/100, &lt;1/10), Uncommon (&ge;1/1,000, &lt;1/100), Rare (&ge;1/10,000, &lt;1/1,000), Very rare (&lt;1/10,000 including isolated cases)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:13.2pt; vertical-align:top; width:132.95pt"><p><strong>System Organ Class</strong></p></td><td style="border-color:black; height:13.2pt; vertical-align:top; width:63.85pt"><p><strong>Frequency</strong></p></td><td style="border-color:black; height:13.2pt; vertical-align:top; width:255.1pt"><p><strong>Adverse Experience Term</strong></p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:132.95pt"><p><strong><em>Immune system disorders:</em></strong></p></td><td style="height:25.8pt; vertical-align:top; width:63.85pt"><p>Rare</p></td><td style="height:25.8pt; vertical-align:top; width:255.1pt"><p>hypersensitivity reactions including urticaria and angioedema</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:132.95pt"><p><strong><em>Metabolism and nutrition</em></strong><strong><em> </em></strong><strong><em>disorders:</em></strong></p></td><td style="height:25.8pt; vertical-align:top; width:63.85pt"><p>Rare</p></td><td style="height:25.8pt; vertical-align:top; width:255.1pt"><p>symptomatic hypocalcaemia, often in association with predisposing conditions&sect;</p></td></tr><tr><td rowspan="2" style="border-color:black; height:13.1pt; vertical-align:top; width:132.95pt"><p><strong><em>Nervous system disorders:</em></strong></p></td><td style="height:13.1pt; vertical-align:top; width:63.85pt"><p>Common</p></td><td style="height:13.1pt; vertical-align:top; width:255.1pt"><p>headache, dizziness&dagger;</p></td></tr><tr><td style="height:13.2pt; vertical-align:top; width:63.85pt"><p>Uncommon</p></td><td style="height:13.2pt; vertical-align:top; width:255.1pt"><p>dysgeusia&dagger;</p></td></tr><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:132.95pt"><p><strong><em>Eye disorders:</em></strong></p></td><td style="height:13.1pt; vertical-align:top; width:63.85pt"><p>Uncommon</p></td><td style="height:13.1pt; vertical-align:top; width:255.1pt"><p>eye inflammation (uveitis, scleritis, episcleritis)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:25.8pt; vertical-align:top; width:132.95pt"><p><strong><em>Ear and labyrinth</em></strong><strong><em> </em></strong><strong><em>disorders:</em></strong></p></td><td style="height:25.8pt; vertical-align:top; width:63.85pt"><p>Common</p></td><td style="height:25.8pt; vertical-align:top; width:255.1pt"><p>vertigo&dagger;</p></td></tr><tr><td style="height:25.8pt; vertical-align:top; width:63.85pt"><p>Very Rare</p></td><td style="height:25.8pt; vertical-align:top; width:255.1pt"><p>osteonecrosis of the external auditory canal</p><p>(bisphosphonate class adverse reaction)</p></td></tr><tr><td rowspan="3" style="border-color:black; height:38.5pt; vertical-align:top; width:132.95pt"><p><strong><em>Gastrointestinal disorders</em></strong></p></td><td style="height:38.5pt; vertical-align:top; width:63.85pt"><p>Common</p></td><td style="height:38.5pt; vertical-align:top; width:255.1pt"><p>abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, acid regurgitation</p></td></tr><tr><td style="height:25.8pt; vertical-align:top; width:63.85pt"><p>Uncommon</p></td><td style="height:25.8pt; vertical-align:top; width:255.1pt"><p>nausea, vomiting, gastritis, oesophagitis*, oesophageal erosions*, melena&dagger;</p></td></tr><tr><td style="height:38.4pt; vertical-align:top; width:63.85pt"><p>Rare</p></td><td style="height:38.4pt; vertical-align:top; width:255.1pt"><p>oesophageal stricture*, oropharyngeal ulceration*, upper gastrointestinal PUBs (perforation, ulcers, bleeding) &sect;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:132.95pt"><p><strong><em>Skin and subcutaneous</em></strong><strong><em> </em></strong><strong><em>tissue disorders:</em></strong></p></td><td style="border-color:black; height:13.1pt; vertical-align:top; width:63.85pt"><p>Common</p></td><td style="border-color:black; height:13.1pt; vertical-align:top; width:255.1pt"><p>alopecia&dagger;, pruritus&dagger;</p></td></tr><tr><td style="height:13.2pt; vertical-align:top; width:63.85pt"><p>Uncommon</p></td><td style="height:13.2pt; vertical-align:top; width:255.1pt"><p>rash, erythema</p></td></tr><tr><td style="height:38.4pt; vertical-align:top; width:63.85pt"><p>Rare</p></td><td style="height:38.4pt; vertical-align:top; width:255.1pt"><p>rash with photosensitivity, severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis&Dagger;</p></td></tr><tr><td rowspan="3" style="border-color:black; height:38.5pt; vertical-align:top; width:132.95pt"><p><strong><em>Musculoskeletal and</em></strong><strong><em> </em></strong><strong><em>connective tissue</em></strong><strong><em> </em></strong><strong><em>disorders:</em></strong></p></td><td style="height:38.5pt; vertical-align:top; width:63.85pt"><p>Very Common</p></td><td style="height:38.5pt; vertical-align:top; width:255.1pt"><p>musculoskeletal (bone, muscle or joint) pain which is sometimes severe&dagger;&sect;</p></td></tr><tr><td style="height:13.1pt; vertical-align:top; width:63.85pt"><p>Common</p></td><td style="height:13.1pt; vertical-align:top; width:255.1pt"><p>joint swelling&dagger;</p></td></tr><tr><td style="height:39.35pt; vertical-align:top; width:63.85pt"><p>Rare</p></td><td style="height:39.35pt; vertical-align:top; width:255.1pt"><p>osteonecrosis of the jaw&Dagger;&sect;; atypical subtrochanteric</p><p>and diaphyseal femoral fractures (bisphosphonate class adverse reaction)^</p></td></tr><tr><td rowspan="2" style="border-color:black; height:13.1pt; vertical-align:top; width:132.95pt"><p><strong><em>General disorders and</em></strong><strong><em> </em></strong><strong><em>administration site</em></strong><strong><em> </em></strong><strong><em>conditions:</em></strong></p></td><td style="height:13.1pt; vertical-align:top; width:63.85pt"><p>Common</p></td><td style="height:13.1pt; vertical-align:top; width:255.1pt"><p>asthenia&dagger;, peripheral oedema&dagger;</p></td></tr><tr><td style="height:38.5pt; vertical-align:top; width:63.85pt"><p>Uncommon</p></td><td style="height:38.5pt; vertical-align:top; width:255.1pt"><p>transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment&dagger;</p></td></tr><tr><td colspan="3" style="border-color:black; height:63.25pt; vertical-align:top; width:451.9pt"><p>&sect;<em>See section 4.4</em></p><p>&dagger;<em>Frequency in Clinical Trials was similar in the drug and placebo group.</em></p><p><em>*See sections 4.2 and 4.4</em></p><p>&Dagger;<em>This adverse reaction was identified through post-marketing surveillance.&nbsp; The frequency of rare was estimated based on relevant clinical trials.</em></p><p>^<em>Identified</em><em> in postmarketing experience.</em></p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Hypocalcaemia, hypophosphataemia and upper gastro-intestinal adverse events, such as upset stomach, heartburn, oesophagitis, gastritis, or ulcer, may result from oral overdosage.</p><p>&nbsp;</p><p><u>Management</u></p><p>No specific information is available on the treatment of overdosage with alendronate. Milk or antacids should be given to bind alendronate. Owing to the risk of oesophageal irritation, vomiting should not be induced and the patient should remain fully upright.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group<strong>: </strong>Bisphosphonate, for the treatment of bone diseases ATC Code: M05B A04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>The active ingredient of FOSAMAX, alendronate sodium trihydrate, is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. Preclinical</p><p>&nbsp;</p><p>studies have shown preferential localisation of alendronate to sites of active resorption. Activity of osteoclasts is inhibited, but recruitment or attachment of osteoclasts is not affected. The bone formed during treatment with alendronate is of normal quality.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Treatment of post-menopausal osteoporosis</em></p><p><em>&nbsp;</em></p><p>Osteoporosis is defined as BMD of the spine or hip 2.5 SD below the mean value of a normal young population or as a previous fragility fracture, irrespective of BMD.</p><p><strong>&nbsp;</strong></p><p>The therapeutic equivalence of FOSAMAX Once Weekly 70 mg (n=519) and alendronate 10 mg daily (n=370) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis. The mean increases from baseline in lumbar spine BMD at one</p><p>year were 5.1% (95% CI: 4.8, 5.4%) in the 70 mg once-weekly group and 5.4% (95% CI: 5.0, 5.8%) in the 10 mg daily group. The mean BMD increases were 2.3% and 2.9% at the femoral neck and 2.9% and 3.1% at the total hip in the 70 mg once weekly and 10 mg daily groups, respectively. The two treatment groups were also similar with regard to BMD increases at other skeletal sites.</p><p>&nbsp;</p><p>The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design (n=994) as well as in the Fracture Intervention Trial (FIT: n=6,459).</p><p>In the initial efficacy studies, the mean bone mineral density (BMD) increases with alendronate 10 mg/day relative to placebo at three years were 8.8%, 5.9% and 7.8% at the spine, femoral neck and trochanter, respectively. Total body BMD also increased significantly. There was a 48% reduction (alendronate 3.2% vs placebo 6.2%) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo. In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained.</p><p>&nbsp;</p><p>FIT consisted of two placebo-controlled studies using alendronate daily (5 mg daily for two years and 10 mg daily for either one or two additional years):</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->FIT 1: A three-year study of 2,027 patients who had at least one baseline vertebral (compression) fracture. In this study alendronate daily reduced the incidence of &sup3;1 new vertebral fracture by 47% (alendronate 7.9% vs. placebo 15.0%). &nbsp;In addition, a statistically significant reduction was found in the incidence of hip fractures (1.1% vs. 2.2%, a reduction of 51%).</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->FIT 2: A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture. In this study, a significant difference was observed in the analysis of the subgroup of osteoporotic women (37% of the global population who correspond with the above definition of osteoporosis) in the incidence of hip fractures (alendronate 1.0% vs. placebo 2.2%, a reduction of 56%) and in the incidence of &sup3;1 vertebral fracture (2.9% vs. 5.8%, a reduction of 50%).</p><p>&nbsp;</p><p><u>Laboratory test findings</u></p><p>&nbsp;</p><p>In clinical studies, asymptomatic, mild and transient decreases in serum calcium and phosphate were observed in approximately 18 and 10%, respectively, of patients taking alendronate 10 mg/day versus approximately 12 and 3% of those taking placebo. However, the incidences of decreases in serum calcium to &lt;8.0 mg/dl (2.0 mmol/l) and serum phosphate to &pound;2.0 mg/dl (0.65 mmol/l) were similar in both treatment groups.</p><p>&nbsp;</p><p><u>Paediatric population:</u></p><p>&nbsp;</p><p>Alendronate sodium has been studied in a small number of patients with osteogenesis imperfecta under the age of 18 years. Results are insufficient to support the use of alendronate sodium in paediatric patients with osteogenesis imperfecta.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Relative to an intravenous reference dose, the oral mean bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast. Bioavailability was decreased similarly to an estimated 0.46% and 0.39% when alendronate was administered one hour or half an hour before a standardised breakfast. In osteoporosis studies, alendronate was effective when administered at least 30 minutes before the first food or beverage of the day.</p><p>&nbsp;</p><p>Bioavailability was negligible whether alendronate was administered with, or up to two hours after, a standardised breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60%.</p><p>&nbsp;</p><p>In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically meaningful change in oral bioavailability of alendronate (a mean increase ranging from 20% to 44%).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine. The mean steady-state volume of distribution, exclusive of bone, is at least 28 litres in humans. Concentrations of drug in plasma following therapeutic oral doses are too low for analytical detection (&lt;5 ng/ml). Protein binding in human plasma is approximately 78%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>There is no evidence that alendronate is metabolised in animals or humans. <u>Elimination</u></p><p>Following a single intravenous dose of [14C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces. Following a single 10 mg intravenous dose, the renal clearance of alendronate was 71 ml/min, and systemic clearance did not exceed 200 ml/min. Plasma concentrations fell by more than 95% within six hours following intravenous administration.</p><p>&nbsp;</p><p>The terminal half-life in humans is estimated to exceed ten years, reflecting release of alendronate from the skeleton. Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats, and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>Preclinical studies show that the drug that is not deposited in bone is rapidly excreted in the urine. No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/kg in animals. Although no clinical information is available, it is likely that, as in animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia. In studies, rats given high doses showed an increased incidence of incomplete foetal ossification. The relevance to humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose</p><p>Lactose anhydrous</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg; C. Store in the original blister in order to protect from moisture and light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/aluminum blisters in cartons containing 2, 4, 8, 12 or 40 tablets. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Manufacturer:
Aesica Pharmaceuticals GMBH
Galileistrasse 6, Zwickau, D-08056, Germany.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                19 June 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>